Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets.

Abstract

BACKGROUND:

Traditional nanodrug delivery systems have some limitations, such as eliciting immune responses and inaccuracy in targeting tumor microenvironments.

MATERIALS AND METHODS:

Targeted drugs (Sorafenib, Sora) nanometers (hollow mesoporous silicon, HMSN) were designed, and then coated with platelet membranes to form aPD-1-PLTM-HMSNs@Sora to enhance the precision of drug delivery systems to the tumor microenvironment, so that more effective immunotherapy was achieved.

RESULTS:

These biomimetic nanoparticles were validated to have the same abilities as platelet membranes (PLTM), including evading the immune system. The successful coating of HMSNs@Sora with PLTM was corroborated by transmission electron microscopy (TEM), western blot and confocal laser microscopy. The affinity of aPD-1-PLTM-HMSNs@Sora to tumor cells was stronger than that of HMSNs@Sora. After drug-loaded particles were intravenously injected into hepatocellular carcinoma model mice, they were demonstrated to not only directly activate toxic T cells, but also increase the triggering release of Sora. The combination of targeted therapy and immunotherapy was found to be of gratifying antineoplastic function on inhibiting primary tumor growth.

CONCLUSIONS:

The aPD-1-PLTM-HMSNs@Sora nanocarriers that co-delivery of aPD-1 and Sorafenib integrates unique biomimetic properties and excellent targeting performance, and provides a neoteric idea for drug delivery of personalized therapy for primary hepatocellular carcinoma (HCC).

• Authors: Xuanbo Da, Bangping Cao, Jiantao Mo, Yukai Xiang, Hai Hu, Chen Qiu, Cheng Zhang, Beining Lv, Honglei Zhang, Chuanqi He, Yulong Yang
• Journal: BMC cancer (BMC Cancer) Vol. 24 Issue 1 Pg. 273 (Feb 26 2024) ISSN: 1471-2407 [Electronic] England
• PMID: 38409035 (Publication Type: Journal Article)
• Copyright: © 2024. The Author(s).

Chemical References

• Sorafenib
• Antineoplastic Agents

Topics

• Animals
• Mice
• Sorafenib (therapeutic use)
• Carcinoma, Hepatocellular (drug therapy, pathology)
• Biomimetics
• Liver Neoplasms (drug therapy, pathology)
• Cell Line, Tumor
• Antineoplastic Agents (pharmacology, therapeutic use)
• Nanoparticles
• Tumor Microenvironment